Creating a new generation of small molecule protease inhibitors

2018 News Releases

Keyword Search
2018 | 2017 | 2016
01/05/18KalVista Pharmaceuticals Commences Two Clinical Trials
– Data Expected for Phase 2 Clinical Trial of KVD001 in Diabetic Macular Edema Patients in the Second Half of 2019 – – Second Oral Hereditary Angioedema Candidate Begins Phase 1 Clinical Trial – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 5, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today an... 
Printer Friendly Version